Myriad Genetics last week launched TheraGuide 5-FU, a DNA-based test to help predict which cancer patients are likely to have adverse reactions to the drug 5-Fluorouracil (5-FU) or the oral form of the drug, capecitabine. The test costs $1,100 and includes DNA sequence analysis of the DPYD and TYMS genes, which increase a patient's risk for toxicity to 5-FU chemotherapy.
Get the full story with
GenomeWeb Premium
Only $95 for the
first 90 days*
GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
You may already have institutional access!
Already a GenomeWeb or 360Dx Premium member?
Login Now.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
Not ready for premium?
Register for Free ContentYou can still register for access to our free content.